Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: TCRX

TScan Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for TCRX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.91

TScan Therapeutics, Inc. (NASDAQ: TCRX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:47 UTC.

What TScan Therapeutics, Inc. does

TScan Therapeutics develops T cell receptor-engineered T cell therapy product candidates for treatment of cancer and other diseases. The company focuses on advancing its TCR-T therapy platform through preclinical studies and clinical trials with the goal of obtaining regulatory approvals and commercializing its product candidates. TScan operates as a research and development organization developing its proprietary platform technology and pursuing development partnerships and collaborations.

Summarized from TScan Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.91
Debt/equity0.47

Revenue, margins & earnings

FY2021: net loss $49M on revenue $10M$10MFY2021FY2022: net loss $66M on revenue $14M$14MFY2022FY2023: net loss $89M on revenue $21M$21MFY2023FY2024: net loss $127M on revenue $3M$3MFY2024FY2025: net loss $130M on revenue $10M$10MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-02
  • 2026-10-02Chief Executive OfficerAward1,000,000—
  • 2026-10-02See RemarksAward300,000—
  • 2026-05-22DirectorStock Option (Right to Buy)Award67,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does TScan Therapeutics, Inc. do?

TScan Therapeutics develops T cell receptor-engineered T cell therapy product candidates for treatment of cancer and other diseases.

When did TCRX last file with the SEC?

TScan Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-22. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:47 UTC. This page is also available as JSON at /api/data?ticker=TCRX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for TCRX and 5,000+ tickers.

Create a free account — keep TCRX
For your agent
GET /api/data?ticker=TCRX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt